← Evidence map

ReviewJournal of hematology & oncology2016

Second- and third-generation ALK inhibitors for non-small cell lung cancer.

Jingjing Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

84 papers cite itlatest 60 shown

2016
…
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 26951079